- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 261/16 - Benzènesulfonamido isoxazoles
Détention brevets de la classe C07D 261/16
Brevets de cette classe: 67
Historique des publications depuis 10 ans
|
1
|
5
|
6
|
6
|
7
|
3
|
3
|
5
|
0
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Xenon Pharmaceuticals Inc. | 190 |
7 |
| Dompé Farmaceutici S.p.A. | 273 |
3 |
| Eastern Virginia Medical School | 66 |
3 |
| The Regents of the University of California, Santa Cruz | 18 |
3 |
| Thomas Jefferson University | 543 |
3 |
| Biofront Ltd. (Cayman) | 15 |
3 |
| Elara Pharmaceuticals GmbH | 9 |
2 |
| European Molecular Biology Laboratory (embl) | 24 |
2 |
| Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | 311 |
2 |
| Sanford-Burnham Medical Research Institute | 126 |
2 |
| Theaprin Pharmaceuticals Inc. | 33 |
2 |
| Shanghai Hansoh Biomedical Co., Ltd. | 276 |
2 |
| Nissan Chemical Corporation | 2084 |
2 |
| The Royal Institution for The Advancement of Learning / McGill University | 698 |
2 |
| The United States of America Department of Health | 2 |
2 |
| Novartis Pharma AG | 102 |
1 |
| Boehringer Ingelheim International GmbH | 4632 |
1 |
| Centre National de La Recherche Scientifique | 10632 |
1 |
| Vertex Pharmaceuticals Incorporated | 1627 |
1 |
| Curegenix, Inc. | 17 |
1 |
| Autres propriétaires | 22 |